AbbVie (ABBV) announced that it has submitted an application for a new indication to the U.S. FDA for upadacitinib for the treatment of adult and adolescent patients with severe alopecia areata, based on results from the Phase 3 UP-AA clinical program.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie submits application to FDA for Skyrizi for subcutaneous induction
- Options Volatility and Implied Earnings Moves This Week, April 27 – May 01, 2026
- Is ABBV a Buy, Before Earnings?
- AbbVie Completes Early ABBV-722 Tablet Study, Offering a Small Boost to Pipeline Visibility
- CrowdStrike, ADMA, Achieve, AbbVie, Valero Trending With Analysts